

1 risk prediction that can account for diverse host genetics and other clinical factors. In this study, we evaluated
2 the utility of human liver organoids (HLOs) for high-throughput DILI risk prediction and in an organ-on-chip
3 system.
4

5
6 **Methods**
7

8 HLOs were derived from 3 separate iPSC lines and benchmarked on two platforms for their ability to model *in*
9 *vitro* liver function and identify hepatotoxic compounds using biochemical assays for albumin, ALT, and AST,
10 microscopy-based morphological profiling, and single-cell transcriptomics: 1) HLOs dispersed in 384-well
11 formatted plates and exposed to a library of compounds. 2) HLOs adapted to a liver-on-chip system.
12

13
14 **Results**
15

16 1) Dispersed HLOs derived from the 3 iPSC lines had similar DILI predictive capacity to intact HLOs in a high-
17 throughput screening format allowing for measurable IC50 values of compound cytotoxicity. Distinct
18 morphological differences were observed in cells treated with drugs exerting differing mechanisms of toxicity.
19 2) On-chip HLOs significantly increased albumin production, CYP450 expression, and ALT/AST release when
20 treated with known DILI drugs compared to dispersed HLOs and primary human hepatocytes. On-chip HLOs
21 were able to predict the synergistic hepatotoxicity of tenofovir-inarigivir and showed steatosis and
22 mitochondrial perturbation via phenotypic and transcriptomic analysis with exposure to FIAU and
23 acetaminophen, respectively.
24

25
26 **Conclusions**
27

28
29 The high throughput and liver-on-chip system exhibit enhanced *in vivo*-like function and demonstrate the
30 potential utility of these platforms for hepatotoxicity risk assessment. Tenofovir-inarigivir associated
31 hepatotoxicity was observed and correlates with the clinical manifestation of DILI observed in patients.
32

33
34 **LAY SUMMARY**
35

36 Idiosyncratic (spontaneous, patient-specific) drug-induced liver injury (DILI) is difficult to study due to the lack
37 of liver models that function as human liver tissue and are adaptable for large-scale drug screening. Human liver
38 organoids grown from patient stem cells respond to known DILI-causing drugs in both a high-throughput and
39 on a physiological “chip” culture system. These platforms show promise in their use as predictive model for
40 novel drugs before entering clinical trials.
41

42
43 **INTRODUCTION**
44

45 Drug-induced liver injury (DILI) is an infrequent but important cause of both acute and chronic liver
46 disease.[1,2] An estimated 22% of clinical trial failures and 32% of market withdrawals of therapeutics are due
47 to hepatotoxicity.[3,4] Hepatotoxicity is typically not identified until clinical trials or post-marketing which
48 creates an increased risk for clinical trial participants as well as a financial burden in drug development. Most
49 instances of DILI are termed “idiosyncratic,” since they are largely independent of the dose and duration of
50 drug use and develop in only a small proportion of treated patients for as-yet unclear reasons. As there are
51 currently over 1000 prescription medications and >80,000 herbal and dietary supplements (HDS) available for
52 use in the United States [5], the potential for additive or synergistic liver toxicity is high with low predictive
53 capability.
54

55 Recently, inarigivir soproxil (GS-9992) was investigated against Hepatitis B (HBV).[6] Inarigivir monotherapy
56 and in combination with tenofovir showed no clear signs of toxicity in two clinical trials for HBV. However, a
57 later phase-2 inarigivir/tenofovir study identified severe DILI in patients given the combination of both drugs
58

1 after 16 weeks of therapy that lead to the discontinuation of this drug development program. All 7 patients had
2 an elevated alanine aminotransferease (ALT) after 16 weeks of therapy, 4 of the 7 had associated
3 hyperbilirubinemia, and one subject died due to multiorgan system failure with lactic acidosis and evidence of
4 hepatic steatosis.[7] This clinical trial emphasizes the need for high fidelity pre-clinical DILI risk prediction.
5 Primary human hepatocyte (PHH) cell cultures currently used in these assays retain hepatocyte function but
6 decline rapidly in metabolic function and vary greatly between cadaveric fresh and cryopreserved samples.[8]
7 PHH availability and source patient diversity is also limited preventing their use in large-scale screening for
8 DILI-risk.[9]

11
12 To meet this challenge, we explored the use of human liver organoids (HLOs) as a more physiologically
13 organotypic system for recapitulating DILI *in vitro*, with added adaptations for high-throughput screening.
14 HLOs consist primarily of hepatocyte-like cells while also containing non-parenchymal stellate-like and
15 Kupffer-like cells derived from the same individual donor.[10] In this study, we utilized a previously-developed
16 protocol for derivation of HLOs from induced pluripotent stem cells (iPSC) [11] allowing for a personalized
17 approach in assessing DILI based on iPSC donor selection. We adapted HLOs both for high-throughput drug
18 screening in 384-well plates and for enhanced physiological fidelity in a liver-chip system (Emulate Bio)[12]
19 previously used to successfully predict species-specific DILI with PHHs.[13,14]

22
23 Due to the complexity and inconsistency of DILI based on culprit drug modality, we developed an integrated
24 multi-omics platform including biomarker/analyte detection, high content imaging-enabled phenotyping, and
25 single-cell RNA sequencing to deliver a comprehensive platform for dissection of DILI with inarigivir +
26 tenofovir as a benchmark. In this study, we demonstrate the potential of dispersed HLOs for rapid 384-well
27 based compound DILI-risk screening, and also the validation of a patient-derived liver-on-chip (PaDLOC)
28 system for a more intricate and mechanistic assessment of DILI pathogenesis.

29
30 **EXPERIMENTAL PROCEDURES**
31

32
33 *PaDLOC Culture and Compound Treatment*
34

35
36 Dispersed HLO cells were transferred to the Chip S1™ based on the co-culture Liver-Chip Culture Protocol as
37 described by Emulate Bio.[15] In brief, both channels were coated with an extracellular matrix consisting of
38 collagen I (100 µg/mL) (Corning, 354249) and fibronectin (25 µg/mL) (ThermoScientific, 33010018) at 4 °C
39 overnight followed by 1 hr at 37 °C. Dispersed HLOs were concentrated to a density of 4 x 10⁶ cells/mL. 50 µL
40 of cell suspension was quickly pipetted into the bottom channel and the chip immediately flipped over to allow
41 attachment to the membrane to allow even dispersion and cultured static (no media flow) at 37 °C for 8 hrs for
42 attachment to the semi-permeable membrane. Next, 30 µL of cell suspension was seeded into the top channel
43 and again left to attach for 8 hrs at 37 °C. Both channels were then washed with hepatocyte growth media
44 containing hepatocyte growth factor, oncostatin M, dexamethasone de-gassed with a 0.45 µm Steriflip-HV
45 Sterile Centrifuge Tube Top Filter Unit (MilliporeSigma, SE1M003M00).

46
47
48 Each seeded Chip S1 was then attached to a respective Pod™ Portable Module. Loaded Pods were placed into
49 the Zoë™ Culture Module at 37 °C. All chips then underwent a regulate cycle followed by a constant flow rate
50 of 30 µL/hr of the reservoir's media for each of both channels modulated by an Orb™ Hub Module. Media
51 outflow collected in respective reservoirs was obtained for ALT, AST, and albumin measurement. Fresh de-
52 gassed hepatocyte growth media was added into the inlet reservoirs every 2 days. Cells were cultured with flow
53 for 7 days before treatment.

54
55
56 After 7 days, residual hepatocyte growth media was aspirated and replaced with hepatocyte growth media
57 containing either 0.1% DMSO, APAP (100 µM), FIAU (1 µM), tenofovir (500 nM), inarigivir soproxil (500
58 nM), or tenofovir and inarigivir soproxil (250 nM and 250 nM). The flow rate was maintained at a constant rate
59 for an additional 7 days and outflow media was collected at days 1, 4, and 7 post-treatment.

1 *Dispersed 384-well HLO culture and drug delivery*

2

3 Dispersed HLOs were seeded in collagen type 1-coated CellCarrier-384 Ultra Microplates (PerkinElmer,
4 6057308) at a seeding density of 8,000 cells/well in hepatocyte growth media. Cells were left to adhere and
5 culture for 48 hrs before treatment with compounds. For screening, compounds were dispensed in 10-point
6 dose-response from 2 nM to 500 μ M using an HP D300e Digital Dispenser. For tenofovir-inarigivir synergy
7 assessment, tenofovir, inarigivir sorpoxil, and in combination were dispensed in triplicate with 12-point dose-
8 response curves in 1/3 dilutions starting with a high of 500 μ M. Cells were then incubated for 120-hours before
9 fixation and staining.

10

11 **RESULTS**

12

13 **Use of Dispersed HLOs in 384-well Based High-Content Screening and Drug Clustering**

14

15 Foregut spheroids from iPSC lines 72.3[16] (male fibroblast derived), 2E[17] (female fibroblast derived), and
16 CC3[18] (female fibroblast derived) were generated through a 6-day differentiation and subsequently
17 differentiated to HLOs over a 20-day period.[10,19] 3D confocal immunofluorescence imaging shows positivity
18 for HNF4A to identify hepatocytes, α -SMA to identify stellate cells, and CD68 to identify Kupffer cells (Fig.
19 S1A-B). Here, we dispensed 3,500 dispersed HLO cells/well in 384-well plates and observed slow proliferation
20 across 7-days while they retained cell-type-specific markers (Fig. S1 A-C) on day 7 of culture. CellProfiler
21 4.2.0[20] cell segmenting determined 64.6-75.2% were positive for HNF4A, 18.7-32.4% for α -SMA, 0.12-
22 0.19% for CD68 and 2.93-5.91% for neither (Fig. S1C). These cell ratios match previously determined cell
23 distribution through single-cell RNA sequencing (scRNA-seq).[10]

24

25 With confirmation of retention of cell type specific markers and ratios in a 384-well format as in intact HLOs, a
26 collection of 12 DILI-associated drugs were screened through HLOs developed through three different iPSC
27 lines to characterize the drug-induced perturbation of single-cells in response to 12 hepatotoxic drugs from 384-
28 well plate screening. These 12 compounds showed dose-responsive loss of cell viability with IC₅₀ values in
29 nanomolar to low micromolar range (Fig. 1A) while neither immortalized hepatocellular carcinoma line Huh7
30 and dispersed definitive endoderm obtained at an earlier development stage exhibited overt cytotoxicity (Fig.
31 S2).

32

33 CellProfiler 4.2.0 was used to segment and extract 845 features per cell to generate a cell-by-feature matrix
34 characterizing drug-induced perturbation of single-cells in response to the 12 hepatotoxic drugs. The
35 dimensionality of the feature vector was reduced to 2-dimensions using the UMAP method[21] and hierarchical
36 density-based clustering was performed with HDBScan[22] to characterize and cluster drug treatments by their
37 resulting phenotypic perturbation. We observe three distinct clusters within this embedding (Fig. 1B, Fig. S3).
38 Cluster α consists largely of allopurinol, tamoxifen, and thioguanine-treated cells. Cluster β largely contains
39 cells treated with nucleotide/nucleoside analogs and consists mainly of cells treated with propylthiouracil, and
40 to a lesser extent, stavudine, and thioguanine-treated cells. Lastly, Cluster γ contains a majority of cells treated
41 with allopurinol and tamoxifen as in Cluster β , but with a major presence of nevirapine and rifampin which are
42 thought to cause DILI through CYP450 modulation.[23] With other compounds, less pronounced clustering was
43 observed (Fig. S3).

44

45 **Biochemical, phenotypic, and transcriptomic analysis of HLOs in an Organ-on-a-Chip System - iPSC
46 Liver Chips**

47

48 Patient-derived liver-on-chips (PaDLOC) were developed by dispersing HLOs into a single-cell suspension
49 seeded in both upper and lower compartments of a dual-compartment microfluidic S1 chip (Emulate Bio) and
50 cultured for an additional 7 days. The dual-compartment microfluidic S1 chip was previously used for long-
51 term culture and maintenance of primary hepatocytes[24]. Primary hepatocytes on this system were shown to

52

53

54

55

56

57

58

59

60

61

62

63

64

65

1 respond to DILI-causing compounds and recapitulate species-specific toxicity over the current preclinical
2 standard models.[13]
3

4 While intact HLOs cultured on plates produce under 10 μ g/mL albumin per day per 10^6 cells with slight
5 diminishment after 7 days of culture, PaDLOCs show an increased albumin production rate of 20-30 μ g/mL per
6 day per 10^6 cells (Fig. 2A). This is comparable to albumin production by PHHs (Gibco, Lot HU8305) on this
7 system and with previous findings while PHHs in plates quickly lost albumin production after few days in
8 culture.[13] PaDLOCs also express CYP450s 1A1, 2D6, and 3A4 at 3-5 fold higher levels as compared to intact
9 HLOs (Fig. S4). Increased CYP expression was also observed by metabolic turnover, as PaDLOCs metabolized
10 acetaminophen (APAP), cyclophosphamide, and darunavir at increased rates compared to plate-cultured intact
11 HLOs (Fig. 2B), albeit at slightly lower rates than PHHs.
12
13

14
15 To confirm the presence of hepatocytes in PaDLOCs and compare the transcriptomic changes imparted by the
16 chip system, we performed scRNASeq of iPSC 72.3 derived HLO cells using the Illumina NovaSeq platform.
17 Single-cell analysis was performed for comparisons of culture conditions (Fig. 2G). Differential expression
18 analysis between all cells of HLOs and PaDLOCs (Fig. 2H) showed an increase of liver proliferation
19 biomarkers TGFB1 (collagen binding) and CCN2 expression (cell adhesion) in PaDLOCs.[25] Increased
20 expression of hepatocyte-marker TDO2, commonly correlated with increased CYPs 1A1 and 1A2[26] and
21 ACTA2, a marker for activated stellate cells[27], were observed. Other liver-specific markers demonstrating
22 increased expression in PaDLOCs include NNMT,[28] and IGFBP7.[29]
23
24

25 **iPSC liver chips for DILI risk prediction**

26

27 Serum biomarkers for DILI include elevated ALT and AST[30] and diminished production of albumin.[31]
28 These biomarkers correspond to hepatocellular injury. APAP and filauridine (FIAU) were chosen as compounds
29 with known intrinsic hepatotoxicity with differing mechanisms of action. APAP is metabolized by CYP450-
30 mediated oxidation to NAPQI which exerts hepatotoxicity via the formation of covalent liver protein adducts at
31 cysteine residues as 3-(cystein-S-yl)-APAP.[32,33] In contrast, FIAU causes hepatotoxicity by stimulating
32 ectopic lipid accumulation and as a mitochondrial toxin. FIAU infamously passed pre-clinical assays but still
33 resulted in overt patient hepatotoxicity.[34,35] For all PaDLOC lines, treatment with 100 μ M of APAP
34 increased ALT from a basal level of less than 10 U/L at day 0 to peaks of around 20-30 U/L (Fig. 2C-D), while
35 treatment with 10 μ M FIAU drastically increased both ALT and AST to over 80 U/L. Additionally, albumin
36 production, a guiding biomarker for the diagnosis of DILI severity,[31] was stable in DMSO-treated PaDLOCs
37 while its production was diminished in both APAP and FIAU-treated PaDLOCs. These observations of
38 ALT/AST release and reduced albumin production were not significant in PHH PaDLOCs (Fig. 2E).
39
40

41

42 The heterogeneity of DILI presents a challenge for DILI-risk prediction for novel therapeutics. For example, in
43 patients, DILI from APAP and FIAU manifest differently due to differing mechanisms of action. APAP has
44 been reported to cause hepatic necrosis[36] whereas FIAU causes diffuse microvesicular steatosis with retention
45 of hepatic architecture.[37] PaDLOCs treated with APAP and FIAU at 100 μ M and 10 μ M, respectively, were
46 stained for nuclei/cell regions and lipid droplets to test if PaDLOCs can capture this heterogeneity. Confocal
47 images demonstrate APAP-treated PaDLOCs showed a patchy loss of cell mask and shriveling of cells with no
48 increased lipid accumulation as compared to control (Fig. 2F). In contrast, FIAU treated PaDLOCs showed high
49 lipid content and a reduction of CellMask staining.
50
51

52

53 **Modeling Hepatotoxicity of Tenofovir and Inarigivir Combinations**

54

55 Cells in 384-well plates were treated with a 16-point dose range of tenofovir, inarigivir soproxil, and tenofovir -
56 inarigivir in combination. After 120 hrs of treatment confocal images were taken for each treatment condition (n
57 = 4 wells) stained to delineate nuclei/cell regions. Striking, while we observed negligible cytotoxicity for the
58 monotherapies up to concentration of 100 μ M, we observed 100% loss of cell viability in the tenofovir-
59 inarigivir combination (Fig. S5A, IC₅₀ = 56.9).
60
61

62

63

64

65

1 In PaDLOCs, tenofovir and inarigivir monotherapy at a concentration near their reported C_{max} (500 nM)[38,39]
2 did not increase ALT or AST release after treatment and no morphological deviation from DMSO-treated
3 control (Fig. 3). However, the combination of tenofovir and inarigivir increased ALT starting at day 4 to 15-25
4 U/L, and to 25-35 at day 7 and AST to 20-30 U/L at day 4 and 40-50 U/L at day 7 (Fig. 3A-B). Combination
5 treatments also resulted in a decrease in albumin production while no effect was observed in the single-agent
6 treatments across the 7 days (Fig. 3C). PaDLOCs from iPSC 72.3 did however demonstrate slight increase in
7 ALT release only at day 7 of treatment.
8

9
10 Visually, PaDLOCs treated with both combinations exhibited a similar phenotype to FIAU-treated controls with
11 regional loss of CellMask staining and high lipid accumulation (Fig. 3D). These features were measured from
12 confocal images and reduced via UMAP into a 2-dimensional projection (Fig. 3E). We note tenofovir-
13 inarigivir-treated cells clustering with those FIAU-treated, while tenofovir and inarigivir single-agent treatments
14 clustered with DMSO control. APAP treated cells exhibited a phenotype unlike either of the other groups and
15 resulted in their unique cluster.
16

17
18
19 **Transcriptomic analysis of Tenofovir-Inarigivir, FIAU, APAP treated PaDLOCs**
20

21 scRNA-seq was performed on drug-treated and control PaDLOCs on the Illumina NovaSeq platform. The
22 concentration and duration of treatment were optimized using phenotypic endpoints to capture intermediate
23 phenotypes rather than late-stage cell death. We evaluated DMSO-treated controls, fialuridine (10 μ M),
24 tenofovir (500 nM), and tenofovir-inarigivir (250 + 250 nM) combination. Single-cell data was subset to the
25 hepatocyte population based on known hepatocyte markers as listed in Fig. 2G. Although tenofovir-inarigivir-
26 induced hepatotoxicity has similar clinical features to that of fialuridine, our comparisons suggest a greater
27 transcriptomic similarity between tenofovir monotherapy and fialuridine. First, UMAP re-embedding of the
28 hepatocytes shows close clustering between fialuridine and tenofovir treatments (Fig. 4A). Volcano plots (Fig.
29 4C) show that both conditions, compared to control, result in overexpression of KCNQ10T1, upregulation of
30 which was previously shown to diminish DILI effect[40] and suppressed expression of RPS10 .
31

32
33
34 Hepatocyte-specific differential expression analysis shows correlative transcriptomic perturbation by fialuridine
35 and tenofovir. Fatty acid, triglyceride, and lipid storage markers (Fig. 4B) were of particular interest due to
36 observations through confocal microscopy (Fig. 3B). DGAT1, involved in triglyceride synthesis and
37 storage,[41] is downregulated under both fialuridine and tenofovir treatment when expression under tenofovir-
38 inarigivir combination treatment matches that of vehicle control. PLIN4, thought to aid in lipid droplet
39 accumulation in the liver,[42] is not detected in the vehicle control but increased in all other conditions. FABP4
40 is expressed consistently in all but the combination treatment, conflicting with previous evidence that FABP4 is
41 overexpressed in liver injury due to hepatocellular carcinoma.[43–45] However, other reports have shown that
42 FABP4 knockdown results in greater adiposity in mice.[46] Across all treatments, we observe diminishment of
43 NDUFA4 as compared to control.[47] We also observed decreased expression of PRDX4 in all treatments, and
44 GSTP1 in fialuridine and tenofovir single treatments, indicators of oxidative stress.[48,49]
45

46
47 As we observed similar transcriptomic perturbations between fialuridine and tenofovir treatments, we assessed
48 whether fialuridine-inarigivir combination treatments showed synergistic toxicity similar to tenofovir-inarigivir
49 treatments. Interestingly, in 384-well dispersed HLO assays, both tenofovir-inarigivir and fialuridine/inarigivir
50 combinatory treatment likely result in synergistic toxicity with calculated Bliss synergy scores of 17.624 and
51 22.964, respectively (Fig. 4D).
52

53
54 **DISCUSSION**
55

56
57 HLOs both from our findings and other reports[50] show promise as a viable *in vitro* model for DILI risk
58 prediction. They are amenable to both a high-throughput screening and adaptation to PaDLOCs to further
59 enhance their organotypic function. Compared to PHHs, HLOs enable large-scale and high throughput DILI
60 risk assessment due to their relative scalability and consistency. Their application in 384-well format serves as
61
62
63
64

1 basis for an early-stage preclinical assessment of novel drugs. PaDLOCs exhibit physiological similarities to
2 human liver including: 1) production of cell types from the same host genetics including hepatocyte-like cells,
3 stellates and Kupffer cells, 2) albumin production, and 3) cytochrome P450 expression.
4

5 HLOs as a dispersed monolayer can minimize well to well variability and obtain clear single-cell resolution
6 images. This enables high-content screening, Cell Painting,[51] and morphological cell profiling. As we
7 demonstrated, these multivariate outputs cluster drugs by their phenotypic perturbation to infer similar
8 mechanisms of action and compare to other compounds. Multivariate analysis also enables cumulative
9 hepatotoxic scores unable to be defined by individual endpoints. For example, FIAU treatment at sub-cytotoxic
10 concentrations results in multidimensional perturbation of cells including diminished mitochondrial mass and
11 lipid accumulation (Fig. S5 B-C). Machine learning-based multivariate analysis can combine multiple features
12 into a robust prediction score.
13

14
15 While high-throughput screening with dispersed HLOs in 384-well plates allows rapid expansion for large
16 screening efforts across multiple iPSC lines, they suffer from lower CYP450 expression and lack of crucial
17 hepatocyte function.[11] Although superior to hepatocellular carcinoma cell lines which often do not
18 demonstrate hepatotoxicity, some observed IC₅₀ values for HLOs loss of cell viability are higher than
19 achievable *in vivo* C_{max}. For example, the reported IC₅₀ for nevirapine in 72.3 derived HLOs is over double that
20 of reported C_{max} in patients.[52] PaDLOCs, likely due to more adequate drug metabolism and mixture of
21 parenchymal and non-parenchymal cell types, seem to respond to many drugs at *in vivo* concentrations.
22

23
24
25 In our studies, fialuridine and tenofovir-inarigivir were administered at C_{max} concentrations and responded with
26 clear hepatotoxicity across multiple cell lines. Hepatotoxicity of both therapies was not detected until clinical
27 trials nor detected in the 384-well platform until higher concentrations. In APAP treatments, previous PHH
28 studies on the Emulate system used 30-fold higher APAP concentrations to achieve a hepatotoxic effect[13],
29 due to reliance of APAP turnover to NAPQI by CYP2E1.[53] Despite greater CYP expression and metabolic
30 turnover, these effects are not observed at the same concentrations in PHHs suggesting also the necessity of the
31 diverse cell types found in intact HLOs and PaDLOCs. Lastly, in patients, APAP and FIAU damaged liver
32 histology present as hepatic necrosis[36] and diffuse microvesicular steatosis with retention of hepatic
33 architecture,[37] respectively. Our confocal images show APAP-treated PaDLOCs with patchy loss of cell mass
34 while FIAU-treatment results in over accumulation of lipids, seemingly mimicking their presentation in patient
35 histology.
36

37
38 The integration of scRNA-seq, shown here as a proof-of-concept for liver chip systems, provides detailed
39 predictive power for synergistic DILI. Herein, our unified multi-omics platform supported with transcriptomics
40 data predicted FIAU-inarigivir synergy given known tenofovir-inarigivir synergy in a complex PaDLOC
41 system, which was then confirmed in 2-dimensional dose response in the higher throughput platform. Although
42 further optimizations are necessary, PaDLOCs show promise as a detailed model for DILI allowing multi-omic
43 endpoints. As they are iPSC-based, and iPSCs can be reprogrammed from patient cells acquired non-invasively
44 (e.g. PBMCs)[54] or even hESCs (Fig. S6), this platform can be expanded to encompass patient genetic
45 diversity. An adequate biobank of PaDLOCs would be ideal to benchmark compounds before clinical trials and
46 mitigate rare hepatotoxic events. Future studies will focus on developing a biobank of complex HLO co-
47 cultures established from idiosyncratic DILI patients thereby concentrating genetics to a screenable number of
48 patient lines as a predictive platform that can capture DILI risk with and enrichment of 10⁶ over the general
49 population.
50

51
52 **Abbreviations:**
53

54 ALT: alanine aminotransferase
55

56 APAP: acetaminophen
57

58

59

60

61

62

63

64

65

1 DILI: drug-induced liver injury

2

3 FIAU: fialuridine

4

5 HLA: human leukocyte antigen

6

7 HLO: human liver organoid

8

9 iPSC: induced-pluripotent stem cells

10

11 PaDLOC: patient-derived liver-on-chip

12

13 PHH: primary human hepatocytes

14

15 scRNA-seq: Single cell RNA sequencing

16

17 UMAP: Uniform Manifold Approximation and Projection

18

19 Acknowledgements:

20

21 The authors would like to thank Emulate Inc. for assistance with experimental design. We thank Kevin Jan at
22 Yokogawa for microscopy support. We thank Teresa O'Meara for writing assistance and proofreading, and
23 Carmen Mirabelli, Chung Owyang, and Bishr Omari for thoughtful advice. We thank Andrew Tidball, Wei
24 Niu, and Xiaotian (Tracy) Qiao for gifting the iPSC lines and providing cell culture support. Lastly, we thank
25 Yihao Zhuang for assistance with acquiring LC/MS data.

26

27 Data Availability:

28

29 All relevant data is provided within this paper and its Supplementary Information. PaDLOC scRNA-seq data
30 have been deposited in the Gene Expression Omnibus (GEO) under accession number GSE188541.

31

32 Supporting Information:

33

34 Supplementary Materials and Methods

35 Fig. S1

36 Fig. S2

37 Fig. S3

38 Fig. S4

39 Fig. S5

40 Fig. S6

41

42 References

43

44 Author names in bold designate shared co-first authorship.

45

46 [1] Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-Induced Liver
47 Injury Network (DILIN) prospective study: rationale, design and conduct. *Drug Saf* 2009;32:55–68.

48 [2] Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, et al. Standardization of nomenclature
49 and causality assessment in drug-induced liver injury: summary of a clinical research workshop.
50 *Hepatology* 2010;52:730–42.

51 [3] Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United
52 Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. *Clin Pharmacol
53 Ther* 1995;58:108–17.

54

55

56

57

58

59

60

61

62

63

64

65

1 [4] Watkins PB. Drug safety sciences and the bottleneck in drug development. *Clin Pharmacol Ther*
2 2011;89:788–90.

3 [5] Gindi R, National Center for Health Statistics (U.S.). Health, United States, 2019 2021.
4 https://doi.org/10.15620/cdc:100685.

5 [6] Yuen M-F, Elkashab M, Chen C-Y, Coffin C, Fung S, Greenbloom S, et al. Dose response and safety of
6 the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B:
7 results from the 25mg and 50mg cohorts in the ACHIEVE trial. *Journal of Hepatology* 2018;68:S509–10.
8 https://doi.org/10.1016/s0168-8278(18)31267-4.

9 [7] Kosh Agarwal, Nezam Afdhal, Carla Coffin, Scott Fung, Geoffrey Dusheiko, Graham Foster, Magdy
10 Elkhashab, Edward Tam, Alnoor Ramji, Radhakrishnan Iyer, Patrick Kennedy. Liver toxicity in the Phase
11 2 Catalyst 206 trial of inarigivir 400mg daily added to a nucleos(t)ide in HBeAg negative patients 2020.

12 [8] Jeffries RE, Gamcsik MP, Keshari KR, Pediaditakis P, Tikunov AP, Young GB, et al. Effect of Oxygen
13 Concentration on Viability and Metabolism in a Fluidized-Bed Bioartificial Liver Using 31P and 13C
14 NMR Spectroscopy. *Tissue Eng Part C Methods* 2013;19:93–100.

15 [9] Stéphenne X, Najimi M, Sokal EM. Hepatocyte cryopreservation: is it time to change the strategy? *World*
16 *J Gastroenterol* 2010;16:1–14.

17 [10] Ouchi R, Togo S, Kimura M, Shinozawa T, Koido M, Koike H, et al. Modeling Steatohepatitis in Humans
18 with Pluripotent Stem Cell-Derived Organoids. *Cell Metab* 2019;30:374–84.e6.

19 [11] Thompson WL, Takebe T. Generation of multi-cellular human liver organoids from pluripotent stem cells.
20 *Methods Cell Biol* 2020;159:47–68.

21 [12] Sheyn D, Cohn-Yakubovich D, Ben-David S, De Mel S, Chan V, Hinojosa C, et al. Bone-chip system to
22 monitor osteogenic differentiation using optical imaging. *Microfluid Nanofluidics* 2019;23.
23 https://doi.org/10.1007/s10404-019-2261-7.

24 [13] Jang K-J, Otieno MA, Ronxhi J, Lim H-K, Ewart L, Kodella KR, et al. Reproducing human and cross-
25 species drug toxicities using a Liver-Chip. *Sci Transl Med* 2019;11.
26 https://doi.org/10.1126/scitranslmed.aax5516.

27 [14] Ewart L, Briggs SA, Carman CV, Chaff JT, Heng AR, Jadalannagari S, et al. Qualifying a human Liver-
28 Chip for predictive toxicology: Performance assessment and economic implications. *bioRxiv*
29 2021:2021.12.14.472674. https://doi.org/10.1101/2021.12.14.472674.

30 [15] Liver-Chip Co-Culture Protocol. Emulate Inc.; 2019.

31 [16] McCracken KW, Catá EM, Crawford CM, Sinagoga KL, Schumacher M, Rockich BE, et al. Modelling
32 human development and disease in pluripotent stem-cell-derived gastric organoids. *Nature* 2014;516:400–
33 4.

34 [17] Dang LT, Vaid S, Lin G, Swaminathan P, Safran J, Loughman A, et al. STRADA-mutant human cortical
35 organoids model megalencephaly and exhibit delayed neuronal differentiation. *Dev Neurobiol*
36 2021;81:696–709.

37 [18] Tidball AM, Neely MD, Chamberlin R, Aboud AA, Kumar KK, Han B, et al. Genomic Instability
38 Associated with p53 Knockdown in the Generation of Huntington's Disease Human Induced Pluripotent
39 Stem Cells. *PLoS One* 2016;11:e0150372.

40 [19] McCracken KW, Howell JC, Wells JM, Spence JR. Generating human intestinal tissue from pluripotent
41 stem cells in vitro. *Nat Protoc* 2011;6:1920–8.

42 [20] Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. CellProfiler: image analysis
43 software for identifying and quantifying cell phenotypes. *Genome Biol* 2006;7:R100.

44 [21] Becht E, McInnes L, Healy J, Dutertre C-A, Kwok IWH, Ng LG, et al. Dimensionality reduction for
45 visualizing single-cell data using UMAP. *Nat Biotechnol* 2018. https://doi.org/10.1038/nbt.4314.

46 [22] McInnes L, Healy J, Astels S. hdbSCAN: Hierarchical density based clustering. *J Open Source Softw*
47 2017;2:205.

48 [23] Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury.
49 *Hepatology* 2013;57:873–4.

50 [24] Dickson I. Multispecies liver-on-a-chip for improved drug toxicity testing. *Nat Rev Gastroenterol Hepatol*
51 2020;17:4.

52

53

54

55

56

57

58

59

60

61

62

63

64

65

1 [25] Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. *Hepatol Res* 2003;26:1–9.

2 [26] Goulart E, de Caires-Junior LC, Telles-Silva KA, Araujo BHS, Kobayashi GS, Musso CM, et al. Adult and
3 iPS-derived non-parenchymal cells regulate liver organoid development through differential modulation of
4 Wnt and TGF- β . *Stem Cell Res Ther* 2019;10:258.

5 [27] Rodansky ES, Johnson LA, Huang S, Spence JR, Higgins PDR. Intestinal organoids: a model of intestinal
6 fibrosis for evaluating anti-fibrotic drugs. *Exp Mol Pathol* 2015;98:346–51.

7 [28] Ding Q, Ma Y, Lai S, Dou X, Li S. NNMT aggravates hepatic steatosis, but alleviates liver injury in
8 alcoholic liver disease. *J Hepatol* 2021;74:1248–50.

9 [29] Allard JB, Duan C. IGF-Binding Proteins: Why Do They Exist and Why Are There So Many? *Front
10 Endocrinol* 2018;9:117.

11 [30] McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers.
12 *EXCLI J* 2016;15:817–28.

13 [31] European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical
14 Practice Guideline Panel: Chair:, Panel members, EASL Governing Board representative: EASL Clinical
15 Practice Guidelines: Drug-induced liver injury. *J Hepatol* 2019;70:1222–61.

16 [32] James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, et al. Pharmacokinetics of
17 acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. *Drug Metab
18 Dispos* 2009;37:1779–84.

19 [33] Dahlin DC, Miwa GT, Lu AY, Nelson SD. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated
20 oxidation product of acetaminophen. *Proc Natl Acad Sci U S A* 1984;81:1327–31.

21 [34] Honkoop P, Scholte HR, de Man RA, Schalm SW. Mitochondrial Injury Lessons from the Fialuridine
22 Trial. *Drug Safety* 1997;17:1–7. <https://doi.org/10.2165/00002018-199717010-00001>.

23 [35] Krähenbühl S. Mitochondria: important target for drug toxicity? *J Hepatol* 2001;34:334–6.

24 [36] Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. *Handb Exp
25 Pharmacol* 2010:369–405.

26 [37] Kleiner DE. Drug-induced liver injury: The hepatic pathologist's approach. *Gastroenterol Clin North Am*
27 2017;46:273–96.

28 [38] Hazra R, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, et al. Single-dose and steady-state
29 pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.
30 *Antimicrob Agents Chemother* 2004;48:124–9.

31 [39] A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a
32 Single Oral Dose of Midazolam in Healthy Subjects n.d. <https://clinicaltrials.gov/ct2/show/NCT03493698>
33 (accessed July 19, 2022).

34 [40] Pei J, Sun X, Yang G, Zhang S. LncRNA KCNQ1OT1 ameliorates the liver injury induced by
35 acetaminophen through the regulation of miR-122-5p/CES2 axis. *Mol Cell Biochem* 2020;475:107–18.

36 [41] Villanueva CJ, Monetti M, Shih M, Zhou P, Watkins SM, Bhanot S, et al. Specific role for acyl
37 CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids.
38 *Hepatology* 2009;50:434–42.

39 [42] Griffin JD, Salter DM, Bowman T, Greenberg A. Role of Hepatic PLIN2 and PLIN4 in The Development
40 of Western Type Diet Induced Hepatosteatosis. *The FASEB Journal* 2017;31:458.3–458.3.

41 [43] Chiyonobu N, Shimada S, Akiyama Y, Mogushi K, Itoh M, Akahoshi K, et al. Fatty Acid Binding Protein
42 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with
43 Metabolic Risk Factors. *The American Journal of Pathology* 2018;188:1213–24.
44 <https://doi.org/10.1016/j.ajpath.2018.01.012>.

45 [44] Thompson KJ, Austin RG, Nazari SS, Gersin KS, Iannitti DA, McKillop IH. Altered fatty acid-binding
46 protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma.
47 *Liver Int* 2018;38:1074–83.

48 [45] Laouirem S, Sannier A, Norkowski E, Cauchy F, Doblas S, Rautou PE, et al. Endothelial fatty liver
49 binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome.
50 *Oncogene* 2019;38:3033–46.

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

1 [46] Yang R, Castriota G, Chen Y, Cleary MA, Ellsworth K, Shin MK, et al. RNAi-mediated germline
2 knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of
3 diet-induced obese mice. *Int J Obes* 2011;35:217–25.
4
5 [47] Pessayre D, Fromenty B, Berson A, Robin M-A, Lettéron P, Moreau R, et al. Central role of mitochondria
6 in drug-induced liver injury. *Drug Metab Rev* 2012;44:34–87.
7
8 [48] Yamada S, Guo X. Peroxiredoxin 4 (PRDX4): Its critical in vivo roles in animal models of metabolic
9 syndrome ranging from atherosclerosis to nonalcoholic fatty liver disease. *Pathology International*
10 2018;68:91–101. <https://doi.org/10.1111/pin.12634>.
11
12 [49] Li T, Zhao X-P, Wang L-Y, Gao S, Zhao J, Fan Y-C, et al. Glutathione S-transferase P1 correlated with
13 oxidative stress in hepatocellular carcinoma. *Int J Med Sci* 2013;10:683–90.
14
15 [50] Shinozawa T, Kimura M, Cai Y, Saiki N, Yoneyama Y, Ouchi R, et al. High-Fidelity Drug-Induced Liver
16 Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids. *Gastroenterology* 2021;160:831–
17 46.e10.
18
19 [51] Bray M-A, Singh S, Han H, Davis CT, Borgeson B, Hartland C, et al. Cell Painting, a high-content image-
20 based assay for morphological profiling using multiplexed fluorescent dyes. *Nat Protoc* 2016;11:1757–74.
21
22 [52] Kappelhoff BS, Huitema ADR, van Leth F, Robinson PA, MacGregor TR, Lange JMA, et al.
23 Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. *HIV Clin Trials*
24 2005;6:254–61.
25
26 [53] Lee SST, Buters JTM, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the
27 Hepatotoxicity of Acetaminophen. *Journal of Biological Chemistry* 1996;271:12063–7.
28
29 https://doi.org/10.1074/jbc.271.20.12063.
30
31 [54] Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent
32 stem cell lines derived from human somatic cells. *Science* 2007;318:1917–20.
33
34

35 Figure Legends

36
37
38
39
40
41
42
43 **Fig. 1. 384-well adaptation of HLOs.** HLOs grown from iPSC lines 72.3, 2E, and CC3 are dispersed into 384-well plates and treated with a 10-point dose response of 12 common DILI causing compounds. After 120 hrs incubation, cells are fixed and stained with Hoechst 33342, MitoView Green, HCS CellMaskOrange, and LipidTox DeepRed and imaged with an automated confocal microscope. (A) IC₅₀ values of these compounds through cell viability counts are calculated (n=4 per concentration, per cell line). (B) CellProfiler was used to extract features at each compound's respective IC₅₀ values for 72.3-derived HLOs and embedded into UMAP. Plot points represent individual cells. Color intensity dictates the percentage of max measurement for each feature.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Fig. 2. Development of a HLO-based Liver Chip. HLOs developed from iPSC lines 72.3, 2E, and CC3 are disrupted into single-cell suspension and cultured into patient-derived liver organoids on chip (PaDLOCs) and compared against intact organoids on 12-well plates. (A) Albumin released in PaDLOCs is identical to that of plate HLOs at day 0 but increases over 7 days (day 21-28 of differentiation). (B) PaDLOCs turnover CYP1A, 2B, and 3A family substrates acetaminophen, cyclophosphamide, and darunavir at increased rate compared to plate HLOs. (C) Cells are treated with DMSO control and known hepatotoxins APAP (100 μ M) and FIAU (1 μ M). PaDLOCs demonstrated both ALT (D) and AST release and (E) albumin production diminishment across 7 days. Bars and plot points represent mean \pm SD (n=3 PaDLOC chips and n=3 plate HLO wells). Statistical significance was calculated using ANOVA with multiple comparison Dunnett's test. *, **, ***, and **** denote P values of less than 0.05, 0.01, 0.001, and 0.0001 respectively. (F) Confocal images of PaDLOCs at day 7 of treatment stained with CellMask Orange (magenta) and LipidTOX Deep Red (cyan). Images shown are scaled to identical intensity ranges. (G) UMAP clustering of 72.3-derived PaDLOCs highlighting a selection of liver specific genes. Each point represents one cell. Gray values represent no detected expression. (H) Volcano plot comparing gene differential expression between 72.3-derived PaDLOC and HLOs with genes most upregulated in PaDLOC highlighted (>0 designates higher expression in PaDLOCs).

1 **Fig. 3. Assessment of known DILI-causing drug combination: tenofovi-inarigivir.** (A) ALT, (B) AST, (C)
2 and albumin released by 72,3, 2E, and CC3 PaDLOCs over 7 days of treatment with tenofovir (500 nM),
3 inarigivir soproxil (500 nM), and tenofovir-xf inarigivir combination (250 + 250 nM) (n=3 chips per condition).
4 Plot points represent mean \pm SD. Statistical significance was calculated using ANOVA with multiple
5 comparison Dunnett's test. *, **, ***, and **** denote P values of less than 0.05, 0.01, 0.001, and 0.0001
6 respectively. (D) PaDLOCs treated with DMSO control, individual agents, combinations, APAP, and FIAU
7 were stained with Hoechst 33342, CellMask Orange, and LipidTOX Deep Red. Images shown are scaled to
8 identical intensity ranges. (E) CellProfiler extracted cell-level features were embedded into UMAP
9 demonstrating morphological clustering. Plot points represent individual cells.
10
11
12

13 **Fig. 4. Single Cell Transcriptomics of treated PaDLOCs.** (A) Hepatocytes across treatments are identified
14 and subset through marker expression and embedded into a UMAP to visualize similarities between treatments.
15 Plot points represent individual cells. (B) Relative expression of *DGAT1*, *PLIN4*, *FABP4*, *NDUFA4*, *PRDX4*,
16 and *GSTP1* in vehicle control, fialuridine, tenofovir, and tenofovir-inarigivir treated PaDLOCs. (C) Volcano
17 plots highlighting significant differential expression between control and drug treatments (>0 designates higher
18 expression in treatment). (D) In 384-well cultures, 2-dimensional dose response assays show inarigivir and both
19 tenofovir and fialuridine are synergistic with Bliss scores of 17.624 and 22.964, respectively, as calculated by
20 SynergyFinder 2.0.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure-1 bioRxiv preprint doi: <https://doi.org/10.1101/2021.08.26.457824>; this version posted July 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




Figure-2 bioRxiv preprint doi: <https://doi.org/10.1101/2021.08.26.457824>; this version posted July 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.







Figure-3 bioRxiv preprint doi: <https://doi.org/10.1101/2021.08.26.457824>; this version posted July 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.







Multi-Omics Data Acquisition



Liver Platform Development



Potential DILI Compounds



Highlights

- Liver organoids retain functionality in a high-throughput platform
- Phenotypic clustering identifies similarities in drug mechanisms of hepatic injury
- Organoids on chip increase albumin and CYP expression; respond to hepatotoxic drugs
- Liver chips model hepatotoxicity of tenofovir-inarigivir combination therapy
- Transcriptomics with morphological profiling predict other synergistic toxicities